India is often referred to as the “Pharma Capital of the World” due to its dominant position in the global pharmaceutical market, particularly in generic drugs and Contract Development and Manufacturing Organizations (CDMOs). India supplies over 40% of the global demand for generics, making it the largest producer of affordable medicines worldwide.
The country’s robust manufacturing infrastructure, skilled workforce, and regulatory compliance make it a hub for pharmaceutical innovation and production. The CDMO sector is also rapidly growing, with India offering cost-effective and high-quality services to global pharmaceutical companies.
With increasing healthcare demands, rising chronic diseases, and expanding access to medicines, India’s pharma sector is poised for significant growth. The future prospects include further expansion in exports, research and development, and biotechnology advancements.
Share Price
The shares of Suven Pharma are currently trading at Rs. 1,152 down by 2.46% from its previous close of Rs. 1,185.15 as of December 23, 2024. The stock also touched an intraday low of Rs. 1,105.
Recent Update
Suven Pharmaceuticals Limited has successfully acquired 56% of the equity share capital of NJ Bio, Inc. (the “Target”) at an aggregate consideration of approximately INR 53.51 crore, which includes a primary equity infusion of INR 12.45 crore into NJ Bio, Inc. The acquisition was completed on December 20, 2024.
This strategic acquisition further strengthens the Company’s position in the market and enhances its capabilities. By acquiring a majority stake in NJ Bio, the Company aims to expand its portfolio and leverage the Target’s innovative technologies and growth potential. This move aligns with the Company’s long-term objectives of expanding its footprint and achieving sustainable growth in the industry.
About the Company
SPL is a Hyderabad-based Contract Development and Manufacturing Organization (CDMO) that provides comprehensive services to leading global pharmaceutical and fine chemical companies, particularly in their New Chemical Entity (NCE) development endeavors. The company offers a wide range of services, including process research and development, late-stage clinical, and commercial manufacturing. SPL is committed to delivering high-quality products that meet customer needs and expectations.
The company specializes in the development of NCE molecules and the supply of intermediates, operating in a high-value-add, high-margin business segment. SPL supplies
intermediates for four key molecules targeting rheumatoid diseases, demonstrating its significant role in advancing therapies for chronic conditions. With a focus on innovation and quality, SPL continues to strengthen its position in the global pharmaceutical and fine chemical markets.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
